Journals / Bakırköy Tıp Dergisi / 2017 / Cilt: 13 - Sayı: 2

Assessment of problems and medication adherence of patients taking oral chemotherapy

Oral kemoterapi alan hastalarda yaşanılan güçlükler ve ilaç uyumunun değerlendirilmesi

Pages
91–97
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Planning the education of nurses about medications according to the needs of patients, increasing patients’ motivations for the process of treatment, and supporting patients for this process in nursing care of oncology and rheumatology patients will enhance the medication adherence of patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The study aimed to assess problems experienced by patients taking oral chemotherapy and their medication adherence.Material and Method: The study used a comparative and descriptive research model and involved 122 patients who were treated through oral chemotherapy in the rheumatology and oncology polyclinics of hospitals at Uludağ University and Eskişehir Osmangazi University and agreed to participate in the study.
📊
Key Findings & Data:The data of the study were collected using a descriptive characteristics questionnaire form and an oral chemotherapy adherence scale.Results: The study sample comprised 47.3% rheumatology patients and 52.7% oncology patients.
💡
Conclusion & Impact:Planning the education of nurses about medications according to the needs of patients, increasing patients’ motivations for the process of treatment, and supporting patients for this process in nursing care of oncology and rheumatology patients will enhance the medication adherence of patients
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The study aimed to assess problems experienced by patients taking oral chemotherapy and their medication adherence.Material and Method: The study used a comparative and descriptive research model and involved 122 patients who were treated through oral chemotherapy in the rheumatology and oncology polyclinics of hospitals at Uludağ University and Eskişehir Osmangazi University and agreed to participate in the study. The data of the study were collected using a descriptive characteristics questionnaire form and an oral chemotherapy adherence scale.Results: The study sample comprised 47.3% rheumatology patients and 52.7% oncology patients. Of the rheumatology patients, 69.8% received treatment because of rheumatoid arthritis. Of the oncology patients, 27.1% received treatment because of colorectal cancer and 54.2% because of breast cancer. The mean of oral medication taken by rheumatology patients was 4.41±4.40 number/day while that taken by oncology patients was 4.51±2.96 number/day. As for oral chemotherapeutics, all patients in the rheumatology group used methotrexate; while of the oncology group, 32.9% used xeloda, 3.4% capecitabine; 24.1% femara; and 22.4% tamoxifen and other oral cytotoxic drugs at lower levels. A total of 35.7% of the rheumatology group and 64.3% of the oncology group experienced problems in the prescription of oral chemotherapeutics. A total of 35.3% of rheumatology patients and 64.7% of oncology patients were not able to establish adequate and effective communication with health professionals. Also, 18.9% of rheumatology patients and 13.8% of oncology patients reported to experience a lack of motivation. A total of, 18.9% of rheumatology patients and 16.9% of oncology patients stated that the medication treatment affected their daily lives in a negative way. No difference was observed between the distribution of oral chemotherapy medication adherence scores of both groups, which were found to be poor (rheumatology=76; oncology=79), (p=0.157).Conclusion and Recommendations: The mean number of medications taken orally by rheumatology and oncology patients on a daily basis was high. Among these medications, the frequency of use and diversity of oral chemotherapeutics in oncology patients was higher than those in rheumatology patients. Factors such as lack of motivation and decrease in self-esteem had negative impact on medication adherences of patients given oral chemotherapeutic. Planning the education of nurses about medications according to the needs of patients, increasing patients’ motivations for the process of treatment, and supporting patients for this process in nursing care of oncology and rheumatology patients will enhance the medication adherence of patients

Özet

Amaç: Bu araştırma oral kemoterapi alan hastalarda yaşanılan güçlükleri ve ilaç uyumunu değerlendirmek amacıyla yapılmıştır.Gereç ve yöntem: Karşılaştırmalı ve tanımlayıcı tipte olan bu araştırma Uludağ Üniversitesi ve Eskişehir Osmangazi Üniversitesi hastanelerinde romatoloji ve onkoloji polikliniklerinde oral kemoterapi ile tedavi edilen, araştırmaya katılmayı kabul eden 112 hasta ile yapılmıştır. Veriler tanıtıcı özellikler anket formu ve oral kemoterapi uyum ölçeği kullanılarak toplanmıştır.Bulgular: Araştırma örnekleminin %47.3'ü romatoloji, %52.7'si onkoloji hastasıdır. Romatoloji hastalarının %69.8'i romatoid artrit; onkoloji hastalarının %27.1'i kolorektal kanser, %54.2'si meme kanseri nedeniyle tedavi edilmektedir. Romatoloji hastaları ortalama 4.41±4.40 adet/gün; onkoloji hastaları ortalama 4.51±2.96 adet/gün oral ilaç kullanırken; oral kemoterapiklerden romatoloji grubunun hepsi metotraxate; onkoloji grubunun %32.9'u xeloda, %3.4'ü kapesitabin, %24.1'i femara, %22.4'ü tamoxifen ve daha düşük oranlarda da diğer oral sitotoksik ilaçları kullandıkları belirlenmiştir. Oral kemoterapiklerin reçetelenmesinde romatoloji grubunun %35.7'sinin, onkoloji grubunun %64.3'nün güçlük yaşadığı; romotoloji hastalarının %35.3'nün, onkoloji hastalarının %64.7'nın sağlık profesyonelleri ile yeterli ve etkili iletişim kuramadıkları; romatoloji hastalarının %18.9'unun, onkoloji hastalarının %13.8'inin motivasyon yokluğu yaşadığı; romatoloji hastalarının %18.9'u, onkoloji hastalarının %16.9'u ilaç tedavisinin günlük yaşamlarını olumsuz yönde etkilediğini bildirmişlerdir. Araştırmada yer alan her iki grubun oral kemoterapi ilaçları uyum puanlarının dağlımı arasında fark yoktur ve her iki grubun ilaç uyumunun kötü olduğu belirlenmiştir (romatoloji=76; onkoloji=79), (p=0.157).Sonuç: Romatoloji ve onkoloji hastalarının günlük oral kullandıkları ortalama ilaç sayıları fazladır. Bu ilaçların içinde oral kemoterapiklerin kullanım sıklığı ve çeşitliliği romatoloji hastalarına göre onkoloji hastalarında daha fazladır. Oral kemoterapik verilen hastaların ilaç uyumlarını motivasyon eksikliği, kendine güvende azalma gibi faktörler olumsuz yönde etkilemektedir. Onkoloji ve romatoloji hastalarının oral kemoterapik ilaç uyumu ile ilgili hemşirelik bakımında; ilaç eğitimlerinin hastanın ihtiyacına yönelik planlanması, hastaların tedavi sürecine ilişkin motivasyonlarının arttırılması ve tedavi süreci ile ilgili desteklenmesi ilaç uyumunu güçlendirecektir

🔖

Cite This Article

ÖZKARAMAN, A., ORLU, N., ATALAY, H. Ö., BABADAĞ, B., YILMAZ, H., DİNÇER, M., ALPARSLAN, G. B. (2017). Assessment of problems and medication adherence of patients taking oral chemotherapy. Bakırköy Tıp Dergisi, Cilt: 13 - Sayı: 2, 91–97. https://ajindex.com/articles/128373

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. American College of Rheumatology. Anti-TNF drugs. Updated March 2015a. https://www.rheumatology.org/Practice/Clinical/ Patients/Medications/Anti-TNF/. Accessed November 11, 2014
  2. Thompson AE, Bashook PG. Rheumatologists recommended patient information when prescribing methotrexate for rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 539-545
  3. Carrington C. Safe use of oral cytotoxic medicines. Australian Prescriber 2013; 36: 9-12
  4. Kav S, Schulmeister L, Nirenberg A, Barber L, Johnson J, Rittenberg C. Development of the MASCC teaching tool for patients receiving oral agents for cancer. Support Care Cancer 2010; 18: 583-590
  5. Grampians Regional Palliative Care Team. Clinical guidelines for the administration of oral chemotherapy agents in the community setting. 2003: 1-36
  6. Barton D. Oral agents in cancer treatment: The context for adherence. Semin Oncol Nurs 2011; 27: 104-115
  7. Szetela AB, Gibson DE. How the new oral antineoplastics affect practice: capecitabine serves to illustrate. Am J Nurs 2007; 107: 40-48
  8. Collins CM, Elsaid KA. Using an enhanced oral chemotherapy computerized provider order entry system to reduce prescribing errors and improve safety. Int J Qual Health Care 2011; 23: 36-43
  9. Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin 2010; 26: 61-69
  10. Kav S, Bostancı H. Role of the nurse in patient education and follow up of people receiving oral chemotherapy treatment in Turkey. Support Care Cancer 2006; 14: 1252-1257
  11. Barefoot J, Blecher CS, Emery R. Keeping pace with oral chemotherapy. Oncology Issues 2009; 3: 36-40
  12. Barillet M, Prevost V, Joly F, Clarisse B. Oral antineoplastic agents: How do we care about adherence? Br J Clin Pharmacol 2015; 80: 1289-1302
  13. Weingart SN, Brown E, Bach PB, et al. NCCN Task Force Report: Oral Chemotherapy. J Natl Compr Canc Netw 2008; 6: S1-14
  14. American College of Rheumatology. Methotrexate (Rheumatrex, Trexall, Otraxup, Rasuva). Updated March 2015b. http://www. rheumatology.org/I-Am-A/Patient-Caregiver/Treatments/ Methotrexate-Rheumatrex-Trexall. Accessed January 24, 2016
  15. Sezgin D, Mert H. Hastalık modifiye edici antiromatizmal ilaç tedavisi alan bireylerin tedavi algılarının uyuma etkisi. DEUHYO ED 2010; 3: 2-8
  16. Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral medications for cancer